Multimodal image-guided surgery of HER2-positive breast cancer using [¹¹¹In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model.

ABSTRACT:

Background

Combining modalities using dual-labeled antibodies may allow preoperative and intraoperative tumor localization and could be used in image-guided surgery to improve complete tumor resection. Trastuzumab is a monoclonal antibody against the human epidermal growth factor-2 (HER2) receptor and dual-labeled trastuzumab with both a fluorophore (IRDye800CW) and a radioactive label (¹¹¹In) can be used for multimodal imaging of HER2-positive breast cancer. The aim of this study was to demonstrate the feasibility of HER2-targeted multimodal imaging using [¹¹¹In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast cancer model.

Methods

Trastuzumab was conjugated with p-isothiocyanatobenzyl (ITC)-diethylenetriaminepentaacetic acid (DTPA) and IRDye800C

SUBMITTER: Deken MM 

PROVIDER: S-EPMC6872692 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature